ENBRIDGE INC. (ENB) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated CAD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated CAD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 29.60B CAD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | |
| Operating income | 11.13B CAD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (CAD) | Revenue (CAD) | Stock-based compensation (CAD) | Operating income (CAD) | Interest expense · reported / estimated (CAD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | 29.60B | (m) | 11.13B | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | 29.52B | (m) | 10.51B | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | 29.33B | (m) | 10.96B | 5.02B | (m) | (m) | 2.18× | Reported |
| 2025-09-30 | (m) | 28.98B | (m) | 10.68B | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | 28.57B | (m) | 10.63B | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | 27.97B | (m) | 10.61B | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | 25.94B | (m) | 9.65B | 4.42B | (m) | (m) | 2.18× | Reported |
| 2024-09-30 | (m) | 24.66B | (m) | 9.05B | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | 24.10B | (m) | 8.62B | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | 23.76B | (m) | 8.70B | 3.81B | (m) | (m) | 2.28× | Reported |
| 2023-12-31 | (m) | 24.20B | (m) | 8.65B | 3.81B | (m) | (m) | 2.27× | Reported |
| 2023-09-30 | (m) | 24.88B | (m) | 6.27B | 3.57B | (m) | (m) | 1.75× | Reported |
| 2023-06-30 | (m) | 25.06B | (m) | 6.25B | 3.46B | (m) | (m) | 1.81× | Reported |
| 2023-03-31 | (m) | 24.64B | (m) | 5.42B | 3.37B | (m) | (m) | 1.61× | Reported |
| 2022-12-31 | (m) | 23.92B | (m) | 5.18B | 3.18B | (m) | (m) | 1.63× | Reported |
| 2022-09-30 | (m) | 22.51B | (m) | 7.82B | 3.05B | (m) | (m) | 2.57× | Reported |
| 2022-06-30 | (m) | 21.41B | (m) | 7.43B | 2.89B | (m) | (m) | 2.57× | Reported |
| 2022-03-31 | (m) | 20.53B | (m) | 7.73B | 2.72B | (m) | (m) | 2.84× | Reported |
| 2021-12-31 | (m) | 19.43B | (m) | 7.80B | 2.65B | (m) | (m) | 2.94× | Reported |
| 2021-09-30 | (m) | 18.82B | (m) | 7.95B | 2.61B | (m) | (m) | 3.05× | Reported |
| 2021-06-30 | (m) | 18.66B | (m) | 8.66B | 2.68B | (m) | (m) | 3.23× | Reported |
| 2021-03-31 | (m) | 18.72B | (m) | 8.99B | 2.74B | (m) | (m) | 3.28× | Reported |
| 2020-12-31 | (m) | 18.82B | (m) | 7.96B | 2.79B | (m) | (m) | 2.85× | Reported |
| 2020-09-30 | (m) | 19.04B | (m) | 7.47B | 2.80B | (m) | (m) | 2.67× | Reported |
| 2020-06-30 | (m) | 19.23B | (m) | 6.97B | 2.73B | (m) | (m) | 2.55× | Reported |
| 2020-03-31 | (m) | 19.48B | (m) | 7.15B | 2.68B | (m) | (m) | 2.67× | Reported |
| 2019-12-31 | (m) | 19.70B | (m) | 8.26B | 2.66B | (m) | (m) | 3.10× | Reported |
| 2019-09-30 | (m) | 19.90B | (m) | 8.01B | 2.63B | (m) | (m) | 3.05× | Reported |
| 2019-06-30 | (m) | 20.05B | (m) | 7.27B | 2.68B | (m) | (m) | 2.71× | Reported |
| 2019-03-31 | (m) | 20.61B | (m) | 6.56B | 2.73B | (m) | (m) | 2.40× | Reported |
| 2018-12-31 | (m) | 21.15B | (m) | 4.82B | 2.70B | (m) | (m) | 1.78× | Reported |
| 2018-09-30 | (m) | 28.98B | (m) | 342.00M | 2.89B | (m) | (m) | 0.12× | Reported |
| 2018-06-30 | (m) | 33.72B | (m) | 978.00M | 2.85B | (m) | (m) | 0.34× | Reported |
| 2018-03-31 | (m) | 39.63B | (m) | 1.09B | 2.73B | (m) | (m) | 0.40× | Reported |
| 2017-12-31 | (m) | 44.38B | (m) | 1.57B | 2.56B | (m) | (m) | 0.61× | Reported |
| 2017-09-30 | (m) | 40.83B | (m) | 4.86B | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | 40.09B | (m) | 3.15B | 1.86B | (m) | (m) | 1.70× | Reported |
| 2017-03-31 | (m) | 36.91B | (m) | 2.27B | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | 34.56B | (m) | 2.58B | 1.59B | (m) | (m) | 1.62× | Reported |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | 33.97B | (m) | 3.59B | 1.87B | (m) | (m) | 1.92× | Reported |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | 33.79B | (m) | 1.86B | 1.62B | (m) | (m) | 1.15× | Reported |
| 2015-06-30 | (m) | 33.65B | (m) | 2.06B | 1.20B | (m) | (m) | 1.72× | Reported |
| 2014-12-31 | (m) | 37.64B | (m) | 3.20B | 1.13B | (m) | (m) | 2.83× | Reported |
| 2014-06-30 | (m) | 37.84B | (m) | 2.33B | 957.00M | (m) | (m) | 2.43× | Reported |
| 2013-12-31 | (m) | 32.92B | (m) | 1.36B | 947.00M | (m) | (m) | 1.44× | Reported |
| 2013-06-30 | (m) | 28.83B | (m) | 1.71B | 870.00M | (m) | (m) | 1.96× | Reported |
| 2012-12-31 | (m) | 25.31B | (m) | 1.51B | 841.00M | (m) | (m) | 1.80× | Reported |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | 27.05B | (m) | 2.63B | 928.00M | (m) | (m) | 2.84× | Reported |
| 2010-12-31 | (m) | 21.52B | (m) | 1.33B | 865.00M | (m) | (m) | 1.53× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.